| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG. |
|
Medicine details |
|
| Medicine name | emicizumab (Hemlibra®) |
| Formulation | 30 mg/1 ml, 60 mg/0.4 ml, 105 mg/0.7 ml and 150 mg/1 ml solution for injection |
| Reference number | 3302 |
| Indication | Routine prophylaxis of bleeding episodes in patients with haemophilia A with factor VIII inhibitors |
| Company | Roche Products Ltd |
| BNF chapter | Nutrition & blood |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 29/03/2018 |